ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,742.69
-0.05%
Dow Jones
42,391.70
0.51%
US Dollar vs MXN
19.68797
0.33%
Brent Oil
71.085
0.19%
Bitcoin
65,841.89
1.01%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. XORTX Therapeutics Inc (XRTX)

  7. XORTX Therapeutics Inc (XRTX) Noticias

XRTX

XORTX Therapeutics (XRTX)

XORTX Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:XRTX
FechaHoraFuenteTítuloSímboloCompañía
24/09/202405:12Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:XRTXXORTX Therapeutics Inc
13/09/202415:20Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XRTXXORTX Therapeutics Inc
13/09/202406:00GlobeNewswire Inc.XORTX Announces Results of Annual and Special Meeting of ShareholdersNASDAQ:XRTXXORTX Therapeutics Inc
12/09/202416:30GlobeNewswire Inc.XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&ANASDAQ:XRTXXORTX Therapeutics Inc
06/09/202416:30GlobeNewswire Inc.XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of ShareholdersNASDAQ:XRTXXORTX Therapeutics Inc
03/09/202411:30GlobeNewswire Inc.Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of ShareholdersNASDAQ:XRTXXORTX Therapeutics Inc
29/08/202406:00GlobeNewswire Inc.XORTX Highlights Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine MetabolismNASDAQ:XRTXXORTX Therapeutics Inc
23/08/202406:00GlobeNewswire Inc.XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of ShareholdersNASDAQ:XRTXXORTX Therapeutics Inc
20/08/202406:00GlobeNewswire Inc.XORTX Announces Presentation at American Society of Nephrology – Kidney Week 2024NASDAQ:XRTXXORTX Therapeutics Inc
04/06/202407:30GlobeNewswire Inc.XORTX to Present at BIO International Convention 2024NASDAQ:XRTXXORTX Therapeutics Inc
17/05/202406:00GlobeNewswire Inc.XORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPONASDAQ:XRTXXORTX Therapeutics Inc
10/05/202415:10Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:XRTXXORTX Therapeutics Inc
30/04/202412:54GlobeNewswire Inc.XORTX Reprices Warrants Issued in Connection with Previous Private PlacementsNASDAQ:XRTXXORTX Therapeutics Inc
22/04/202406:00GlobeNewswire Inc.XORTX Announces Publication of Key Research in ADPKDNASDAQ:XRTXXORTX Therapeutics Inc
08/04/202406:30GlobeNewswire Inc.XORTX Welcomes New Member to the Board of DirectorsNASDAQ:XRTXXORTX Therapeutics Inc
08/04/202406:00GlobeNewswire Inc.XORTX Announces Participation in Spring 2024 Investor ConferencesNASDAQ:XRTXXORTX Therapeutics Inc
27/03/202404:00GlobeNewswire Inc.XORTX Announces New Clinical Advisory Board MemberNASDAQ:XRTXXORTX Therapeutics Inc
19/03/202404:00GlobeNewswire Inc.XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical TrialNASDAQ:XRTXXORTX Therapeutics Inc
04/03/202406:00GlobeNewswire Inc.XORTX Finalizes $2.7 Million Prospectus Supplement and Concurrent Private Placement for the Offering of UnitsNASDAQ:XRTXXORTX Therapeutics Inc
15/02/202406:00GlobeNewswire Inc.XORTX Raises $2.5 Million Under Prospectus Supplement and Concurrent Private Placement for the Offering of UnitsNASDAQ:XRTXXORTX Therapeutics Inc
01/02/202419:46GlobeNewswire Inc.XORTX Files an Amended and Restated Prospectus Supplement for the Offering of UnitsNASDAQ:XRTXXORTX Therapeutics Inc
15/01/202406:00GlobeNewswire Inc.XORTX Announces $2 Million Public OfferingNASDAQ:XRTXXORTX Therapeutics Inc
03/01/202406:00GlobeNewswire Inc.XORTX Submits a New Patent for the Treatment of Chronic Kidney DiseaseNASDAQ:XRTXXORTX Therapeutics Inc
30/11/202306:30GlobeNewswire Inc.XORTX Announces US ATM OfferingNASDAQ:XRTXXORTX Therapeutics Inc
29/11/202320:57Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:XRTXXORTX Therapeutics Inc
29/11/202306:00GlobeNewswire Inc.XORTX Meets Nasdaq Continued Listing RequirementsNASDAQ:XRTXXORTX Therapeutics Inc
10/11/202306:00GlobeNewswire Inc.XORTX Clarifies Timing for Share ConsolidationNASDAQ:XRTXXORTX Therapeutics Inc
08/11/202316:00GlobeNewswire Inc.XORTX Announces Share ConsolidationNASDAQ:XRTXXORTX Therapeutics Inc
02/11/202306:00GlobeNewswire Inc.XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2023NASDAQ:XRTXXORTX Therapeutics Inc
27/10/202316:30GlobeNewswire Inc.XORTX Announces Results of Special Meeting of ShareholdersNASDAQ:XRTXXORTX Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:XRTX

Su Consulta Reciente

CCOM
OILBRENT
Brent Oil
CCOM
US30
US 30
USOTC
BNPQY
BNP Paribas (QX)
NYSE
NKE
Nike
USI
USTECH100
US Tech 100
PM
XAUUSD
Gold vs US Dollar
NYSE
MRK
Merck
FX
EURUSD
Euro vs US Dollar
AMEX
XLV
Health Care Select Sector
AMEX
SPY
SPDR S&P 500
FX
EURMXN
Euro vs MXN
NYSE
MCD
McDonalds
COIN
ADAUSD
Cardano
USOTC
RHHBY
Roche (QX)
NASDAQ
MSFT
Microsoft
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados